Recruiting NCT06115603
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Cannabigerol, Placebo.
- Who it may be relevant to
- Registry conditions: Attention-Deficit/Hyperactivity Disorder. Basic parameters: 18 years — 55 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
CBG and Attention: A Double-Blind, Randomized, Placebo-Controlled Trial Examining the Effects of Cannabigerol on Indicators of Attention-Deficit/Hyperactivity Disorder
Overview
The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.
Interventions
- Drug Cannabigerol
1 mL of 80mg Cannabigerol once during experimental session - Other Placebo
1 mL of placebo once during experimental session
Primary outcome measures
- Sustained Attention to Response Task [Time frame: 75 minutes post CBG/placebo administration]
- Trail Making Test-Parts A and B (TMT-A&B) [Time frame: 75 minutes post CBG/placebo administration]
- Digit Symbol Substitution Test (DSST) [Time frame: 75 minutes post CBG/placebo administration]
- Rey Auditory Verbal Learning Test (AVLT) [Time frame: 75 minutes post CBG/placebo administration]
- Iowa Gambling Task (IGT) [Time frame: 75 minutes post CBG/placebo administration]
Secondary outcome measures (7)
- Positive and Negative Affect Scale-Expanded Version [Time frame: Baseline, 45 minutes post CBG/placebo administration, 75 minutes post CBG/placebo administration]
- Karolinska Sleepiness Scale [Time frame: Pre CBG/placebo administration, 75 minutes post CBG/placebo administration]
- Brief Irritability Test [Time frame: Pre CBG/placebo administration, 75 minutes post CBG/placebo administration]
- Numeric Rating Scale (pain) [Time frame: Pre CBG/placebo administration, 75 minutes post CBG/placebo administration]
- State-Trait Anxiety Inventory (State Version) [Time frame: Pre CBG/placebo administration, 75 minutes post CBG/placebo administration]
- Visual Analog Scales [Time frame: 75 minutes post CBG/placebo administration]
- Global Impression of Change [Time frame: 75 minutes post CBG/placebo administration]
Eligibility criteria
- Between 18 and 55-years-old.
- BMI between 18 and 35 kg/m2.
- Score a 4 or above on the Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist Part A.
- Meet diagnostic criteria for ADHD with a current severity rating of at least mild as defined by the DIAMOND.
- Are not pregnant or currently breastfeeding.
- Have no history of significant allergic condition, hypersensitivity, or allergic reactions to cannabis, cannabinoid medications, hemp products, medium chain triglyceride oil, or peppermint.
- Have not used CBG or any other cannabinoid products in the past 30 days.
- Willing to abstain from using cannabis or any THC-containing product for the duration of the study.
- Have never used a synthetic cannabinoid or cannabinoid analogue (e.g., dronabinol, nabilone), or a synthetic cannabinoid receptor agonist (e.g., spice, k2).
- Have not been exposed to any investigational drug or device 30 days prior to screening and you have no plans to take an investigational drug during the study.
- Willing to maintain a stable treatment regimen (i.e., no change in current medication use) for the duration of the study.
- Not currently taking a prescription medication for ADHD and have not been prescribed a medication for ADHD in the past six months.
- Not currently having thoughts of committing suicide
- Does not meet criteria for current severe major depressive disorder or a substance use disorder.
- Have not been diagnosed with bipolar disorder or psychosis.
- Do not have an acute illness, such as a respiratory infection or other illness that would interfere with study participation; not currently taking medication for an acute illness (e.g., antibiotic).
- Do not have history of diagnosis related to liver function and/or significantly impaired liver function (e.g., cirrhosis of the liver, hepatitis).
- Willing to ensure they have used effective contraception (for example, oral contraception, double barrier, intra-uterine device) for 30 prior to the study and for 30 days after study completion.
- Have access to a ride to the University of Arkansas campus for research appointments.
- Willing to comply with current university mandates as they pertain to COVID-19 protocols (e.g., mask wearing).
- Do not have any serious or unstable physical health conditions including neurological or renal illness.
- Do not have any current or historical cardiovascular conditions, including hypotension, bradycardia, or heart block.
- No atrial fibrillation, bradycardia, or tachycardia detected via mobile electrocardiogram during the in-laboratory visit.
- No recent illicit drug use other than cannabis, or alcohol use in the 12 hours preceding the in-laboratory visit.
- Not currently prescribed or taking the following medications:
- Warfarin
- Clobazam
- Valproic acid
- Phenobarbital
- Mechanistic Target of Rapamycin \[mTOR\] Inhibitors
- Oral tacrolimus
- St. John's wort
- Epidiolex
- Escitalopram
- Cardiovascular medications
- Strong CYP3A4 inhibitors (e.g., ketoconazole)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
United States · 1 center
- University of Arkansas — Fayetteville
Identifiers
NCT: NCT06115603 · 2309494774